Quantcast

Latest Amylin Stories

2011-06-20 15:15:00

SAN DIEGO, June 20, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes drug candidates BYDUREON(TM) (exenatide extended-release for injectable suspension) and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes...

2011-06-08 15:17:00

INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals for a preliminary injunction that sought to impose restrictions on the Lilly Diabetes sales force and other relief. Amylin recently filed litigation involving the two companies' diabetes collaboration agreement. "We are...

2011-06-04 10:45:00

SAN DIEGO, June 4, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy. Data from this study, the first findings from patients receiving metreleptin through Amylin's lipodystrophy expanded access program, were presented at the 93rd Annual Meeting and...

2011-05-31 15:15:00

SAN DIEGO, May 31, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 12:20 p.m. ET / 9:20 a.m. PT in Palos Verdes, California and at the Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate...

2011-05-26 00:22:00

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) ("Amylin" or "the Company") today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company (NYSE: LLY) ("Lilly") relating to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement. The U.S. District Court restrained Lilly from proceeding with its plans to use the same sales...

2011-05-25 21:30:00

INDIANAPOLIS, May 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today commented on a ruling issued by the U.S. District Court for the Southern District of California granting a request by Amylin Pharmaceuticals for a temporary restraining order (TRO) related to litigation involving the two companies' diabetes collaboration agreement. "We are disappointed with the Court's decision to grant a temporary restraining order in this case," said Robert A. Armitage, senior vice...

2011-05-17 15:15:00

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Annual Meeting of Stockholders on Tuesday, May 24, 2011 at 9:00 a.m. PT/12:00 p.m. ET from the Company's corporate headquarters in San Diego, CA. Following the Annual Meeting, Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview. To access the webcast, please log on to the "Investors" section of Amylin's corporate website at...

2011-05-16 13:05:00

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California. The lawsuit alleges that Lilly is not using commercially reasonable efforts to support the success of BYETTA® (exenatide injection) and ultimately, BYDUREON(TM) (exenatide extended-release for injectable suspension). "We...

2011-05-16 05:52:00

SAN DIEGO, May 16, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) ("Amylin" or "the Company") today announced that it has filed a lawsuit against Eli Lilly and Company (NYSE: LLY) ("Lilly") in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide. In 2002, Amylin entered an alliance with...

2011-05-10 07:00:00

NEW YORK and SAN DIEGO, May 10, 2011 /PRNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that they have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide, an analog of the human hormone amylin, with insulin to treat type 1 diabetes. Pramlintide, marketed by Amylin as SYMLIN®...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related